ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
0.54
0.03
(5.88%)
Cerrado 27 Noviembre 3:00PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.54
Postura de Compra
0.51
Postura de Venta
0.57
Volume Operado de la Acción
1,500
0.54 Rango del Día 0.54
0.48 Rango de 52 semanas 2.85
Precio Anterior
0.51
Precio de Apertura
0.54
Última hora de negociación
Volumen promedio (3 m)
26,135
Volumen financiero
-
Precio Promedio Ponderado
-

DTC Últimas noticias

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

 DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER  Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

  Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9   Vancouver, BC, Canada, January 26th...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER   Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

 DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

  VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS   Vancouver, BC, Canada, November...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

  DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER   Vancouver, BC, Canada, October 13th...

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

    DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

 DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

 DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.01-1.818181818180.550.570.5172560.51241173CS
4-0.05-8.474576271190.590.670.51217190.57849862CS
12-0.06-100.60.670.48261350.5764456CS
26-0.66-551.21.20.48318350.73685318CS
52-2.14-79.85074626872.682.850.48290241.18019255CS
156-5.11-90.44247787615.655.80.48190982.18682875CS
260-1.21-69.14285714291.758.150.48183962.60698588CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
GTTXGeneTether Therapeutics Inc
$ 0.11
(175.00%)
2k
EPIC1CM Inc
$ 0.60
(140.00%)
1.12k
CHGXChitogenX Inc
$ 0.01
(100.00%)
5k
CACR.AKWG Resources Inc
$ 2.31
(71.11%)
100
CLDVCloud3 Ventures Inc
$ 0.025
(66.67%)
4.89M
MLKMMayo Lake Minerals Inc
$ 0.025
(-50.00%)
373k
WRUNWaverunner Capital Inc
$ 0.005
(-50.00%)
105.49k
SLZSlave Lake Zinc Corp
$ 0.01
(-50.00%)
9k
MILIMilitary Metals Corp
$ 0.345
(-47.73%)
2.28M
VIBEVibe Growth Corporation
$ 0.11
(-47.62%)
1.5k
RGXRegenx Tech Corp
$ 0.01
(-33.33%)
5.25M
CLDVCloud3 Ventures Inc
$ 0.025
(66.67%)
4.89M
PRMEPrime Drink Group Corp
$ 0.315
(5.00%)
3M
MILIMilitary Metals Corp
$ 0.345
(-47.73%)
2.28M
BTCBluesky Digital Assets Corp
$ 0.74
(-6.33%)
2.12M